UHT Stock Analysis: Universal Health Realty | NYSE
REIT - Healthcare Facilities | NYSE, USA | Market Cap: 608m USD | 12M Return: 16.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.48M
EPS Trend: 28.8%
Rev. Trend: 57.4%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Universal Health Realty Income Trust (NYSE: UHT) is a Maryland-incorporated real estate investment trust (REIT) that invests in healthcare and human service-related facilities, including acute care hospitals, behavioral healthcare facilities, rehabilitation hospitals, sub-acute care facilities, surgery centers, childcare centers, and medical office buildings. Founded in 1986 and headquartered in King of Prussia, Pennsylvania, the Trust holds seventy-seven investments across twenty-one states and trades as a small-cap stock following its 1987 IPO.
As a healthcare REIT, UHT generates revenue primarily through leasing arrangements with operators of medical and human service facilities, a model that typically involves long-term, triple-net leases and requires the Trust to comply with REIT-specific tax regulations that mandate distribution of most taxable income to shareholders.
- Rising interest rates pressure healthcare REIT valuations and dividend yields
- Tenant concentration with Universal Health Services impacts rental income stability
- Medicare and Medicaid reimbursement cuts threaten hospital operator lease payments
| Net Income: 19.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 0.55 > 1.0 |
| NWC/Revenue: -357.1% < 20% (prev 7.61%; Δ -364.7% < -1%) |
| CFO/TA 0.09 > 3% & CFO 49.4m > Net Income 19.3m |
| Net Debt (390.6m) to EBITDA (45.9m): 8.51 < 3 |
| Current Ratio: 0.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (13.9m) vs 12m ago 0.18% < -2% |
| Gross Margin: 79.89% > 18% (prev 94.39%; Δ -14.50% > 0.5%) |
| Asset Turnover: 17.41% > 50% (prev 17.20%; Δ 0.21% > 0%) |
| Interest Coverage Ratio: 0.46 > 6 (EBIT TTM 16.9m / Interest Expense TTM 36.5m) |
| A: -0.63 (Total Current Assets 19.5m - Total Current Liabilities 374.0m) / Total Assets 567.1m |
| B: -0.21 (Retained Earnings -121.5m / Total Assets 567.1m) |
| C: 0.03 (EBIT TTM 16.9m / Avg Total Assets 570.1m) |
| D: 0.34 (Book Value of Equity 143.9m / Total Liabilities 423.2m) |
| Altman-Z'' = -4.24 = D |
| DSRI: 0.13 (Receivables 12.7m/97.8m, Revenue 99.3m/98.6m) |
| GMI: 1.18 (GM 94.39% / 79.89%) |
| AQI: 1.00 (AQ_t 0.95 / AQ_t-1 0.95) |
| SGI: 1.01 (Revenue 99.3m / 98.6m) |
| TATA: -0.05 (NI 19.3m - CFO 49.4m) / TA 567.1m) |
| Beneish M = -3.58 (Cap -4..+1) = AAA |
As of July 29, 2026, the stock is trading at USD 44.28 with a total of 79,530 shares traded. Over the past week, the price has changed by +1.28%, over one month by +0.91%, over three months by +10.54% and over the past year by +16.54%.
Current recommended Stop Loss: 41.50 (which is 6.3% or 2.5 ATR below the current price).
Universal Health Realty has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy UHT.
- StrongBuy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 42 | -5.1% |
P/E Trailing = 34.2422
P/E Forward = 38.7597
P/S = 6.0233
P/B = 4.1147
P/EG = 0.6292
Revenue TTM = 99.3m USD
EBIT TTM = 16.9m USD
EBITDA TTM = 45.9m USD
Long Term Debt = 18.4m USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.32m USD (from shortTermDebt, last fiscal year)
Debt = 397.4m USD (from shortLongTermDebtTotal, last fiscal year) + Leases 11.4m
Net Debt = 390.6m USD (calculated: Debt 397.4m - CCE 6.82m)
Enterprise Value = 998.8m USD (608.2m + Debt 397.4m - CCE 6.82m)
Interest Coverage Ratio = 0.46 (Ebit TTM 16.9m / Interest Expense TTM 36.5m)
EV/FCF = 20.21x (Enterprise Value 998.8m / FCF TTM 49.4m)
FCF Yield = 4.95% (FCF TTM 49.4m / Enterprise Value 998.8m)
FCF Margin = 49.80% (FCF TTM 49.4m / Revenue TTM 99.3m)
Net Margin = 19.41% (Net Income TTM 19.3m / Revenue TTM 99.3m)
Gross Margin = 79.89% ((Revenue TTM 99.3m - Cost of Revenue TTM 20.0m) / Revenue TTM)
Gross Margin QoQ = none% (prev 70.59%)
Tobins Q-Ratio = 1.76 (Enterprise Value 998.8m / Total Assets 567.1m)
Interest Expense / Debt = 9.18% (Interest Expense 36.5m / Debt 397.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 13.3m (EBIT 16.9m * (1 - 21.00%))
Current Ratio = 0.05 (Total Current Assets 19.5m / Total Current Liabilities 374.0m)
Debt / Equity = 2.76 (Debt 397.4m / totalStockholderEquity, last quarter 143.9m)
Debt / EBITDA = 8.51 (Net Debt 390.6m / EBITDA 45.9m)
Debt / FCF = 7.90 (Net Debt 390.6m / FCF TTM 49.4m)
Total Stockholder Equity = 150.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.38% (Net Income 19.3m / Total Assets 567.1m)
RoE = 12.79% (Net Income TTM 19.3m / Total Stockholder Equity 150.7m)
RoCE = 9.99% (EBIT 16.9m / Capital Employed (Equity 150.7m + L.T.Debt 18.4m))
RoIC = 2.37% (NOPAT 13.3m / Invested Capital 562.2m)
WACC = 6.87% (E(608.2m)/V(1.01b) * Re(6.62%) + D(397.4m)/V(1.01b) * Rd(9.18%) * (1-Tc(0.21)))
Discount Rate = 6.62% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 96.77 | Cagr: 0.17%
[DCF] Terminal Value 76.16% ; FCFF base≈48.4m ; Y1≈50.9m ; Y5≈59.0m
[DCF] Fair Price = 37.41 (EV 909.6m - Net Debt 390.6m = Equity 519.0m / Shares 13.9m; r=8.35% [WACC [floored]]; 5y FCF grow 5.66% → 2.50% )
EPS Correlation: 28.80 | EPS CAGR: 1.93% | SUE: N/A | # QB: 0
Revenue Correlation: 57.37 | Revenue CAGR: 10.91% | SUE: -3.93 | # QB: -1
EPS current Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-09-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | GrowthEPS=+0.0% | GrowthRev=-0.1%
EPS next Year (2027-12-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | GrowthEPS=+0.0% | GrowthRev=+5.2%